Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)
In this real-world cohort, irAEs were frequent and clinically diverse. Using adjusted landmark analysis and time-dependent Cox regression, early-onset irAEs were associated with inferior survival in our cohort. Poor baseline PS was linked to an increased risk of cardiac irAEs. Older adults were at a higher risk of dermatological irAEs. Some factors such as higher number of ICI treatment cycles, thrombocytopenia and elevated TSH at baseline may aid in risk stratification. These findings reinforce the need for timely detection and multidisciplinary management of irAEs to optimize ICI safety and effectiveness.
Authors
- Arwa O. Sahal
- Rawan Dawoud (ORCID: https://orcid.org/0000-0002-3007-839X)
- Nabil E. Omar (ORCID: https://orcid.org/0000-0001-8291-7987)
- Shereen Elazzazy (ORCID: https://orcid.org/0000-0002-0017-4401)
- Hebatalla M. Afifi
- Hazem Elewa (ORCID: https://orcid.org/0000-0003-1594-1199)
- Mohamed Saad (ORCID: https://orcid.org/0000-0002-2221-4216)
- Maria Benkhadra (ORCID: https://orcid.org/0000-0002-2382-3021)
- Aya Alasmar
- Sara Nasser (ORCID: https://orcid.org/0000-0002-5719-7532)
- Amaal Gulied (ORCID: https://orcid.org/0000-0002-7712-7363)
- Farah I. Jibril
- Anas Hamad (ORCID: https://orcid.org/0000-0001-8606-8521)
- Mohamed S. Hamid
- Afnan Alnajjar
Institutions
- National Center for Cancer Care and Research (QA)
- Hamad Medical Corporation (QA)
- Qatar University (QA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1665716
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Hamad Medical Corporation